IPCI warrants are in the money at $2.55 and $2.10 and represent $1.8 million. Assuming they were exercised, that is $1.8 million which would hold company for another quarter even without PAR Pharma milestone payment. Also, PAR Pharma instantly launched 15mg and 30mg product days after approval. That means PAR Pharm was anticipating approval. That was surprising considering you keep wailing about IPCI has no sales, no approvals...
IPCI is a generic drug pharmaceutical. It is not a biotech. It is not new-drug pharmaceutical. So it is a boring generic drug company like Lannett, Hi-Tech Pharmacal, Mylan, Actavis (Watson), Impax, and Teva. If IPCI gets to break-even with generic Focalin, I would hold and accumulate IPCI for the next 5 to 10 years and watch it grow to a billion dollar company.
Would Fabry drug qualify as FDA breakthrough? A breakthrough is a substantial improvement over existing drugs. So PRX-102, Fabry drug, has half-life of 581 minutes versus existing enzymes with a 13 minute half-life. Longer half-life should allow enzyme to be absorbed by organs.
How about oral Gaucher's drug for breakthrough? Can you think of any substantial clinical benefit over existing therapies? Maybe less immunogenicity?
In the next 3 to 6 months Protalix finishing up pediatric study for Elelyso, finishing up Fabry phase 1 and 2, and finishing up oral Gaucher's enzyme phase 1. I think oral Gaucher's enzyme is the same as Elelyso, so maybe it can get quicker approval, assuming oral administration works.
mitch2bdog wrote: "I bat a thousand on news plain and simple." I recall you predicted two substantive news items before earnings one quarter and one did not show up. One news item was Gelclair launch, which was obvious, the other one never appeared as there was no news leading up to earnings or weeks after earnings.
petecook68 wrote: "sold it today at .72...not a bad day...." If you use default FIFO (First In First Out) for tax reporting, then your sold shares would match up with earlier purchased shares. Since you bought way higher, you probably generated a stock loss.
Mitch2bdog wrote 4 hours ago: "transfer the listing of its common stock from the NASDAQ Global Market" Oops, Mitch2bdog just realized that DARA is listed on NASDAQ Capital Market, the lowest tier on NASDAQ. He has been following DARA for years.
Hey Gregory03.alan reappeared. Either you are a paid basher or got nothing better to do, or a bot.
IPCI options are also in the money, in addition to warrants. Roughly $23 million of existing dilution. Someone pointed out the Oct 2013 presentation on website listed existing warrants and options. It says there are warrants with an average price $2.46 for 2.8M shares and options with an average price of $3.95 for 4.5M shares. Warrants would raise roughly $6 million and options would raise roughly $17 million. Outstanding shares would rise from 21 million to 28 million.
Anyway, hope many exercise their IPCI warrants and options. Early investors deserve to be rewarded and company needs capital. So there probably is no need for any new dilution if IPCI share price stays above $3 for the warrants and above $4 for the options.
IPCI WARRANTS are IN THE MONEY and exercisable at $2.55 and $2.05. Represents about $1.8 million. In July 2013 company issued 375,000 warrants with an exercise price of $2.55. In March 2013, company issued 453,750 warrants with an exercise price of $2.05. They are 5 year warrants. So assuming investors exercised the warrants in this rally, a DILUTION is not necessary at least for another quarter. Of course, there is the PAR Pharma milestone payment for approval, but there has been no news on that yet.
Watson approved for 30mg on 11/21/2013. Teva got approved for 5mg, 10mg, 20mg, 40mg on 11/19/2013. IPCI got approved for 15mg and 30mg on 11/18/2013.
Teva generic website said they launched 40mg. Mylan got approved for 30mg a few months ago, 8/28/2013, but only announced launch last week. So news about others also getting approved probably put pressure on IPCI stock after the initial rally on Monday. Of course, I am referring to ANDA's for Dexmethylphenidate HCL or generic Focalin.
Some analyst wrote IPCI and TEVA agreed to 180 day co-exclusive launch for lower doses. Is that true or false? I have not found anything about that on IPCI website or filings. At this time, IPCI only has FDA tentative approval on lower doses, 5mg, 10mg, and 20mg, probably because TEVA filed first and has been assigned the 180 day exclusivity.
Holywallst wrote:"have seen bio stocks do that." IPCI is not a bio. It is a pharma. It develops mostly generics. Even the name contains the word pharma. You must be dense to keep calling it a biotech and comparing it to biotech stocks.
Sentiment: Strong Buy
Savient in Chapter 11 bankruptcy. DARA's COO was former Savient CEO that steered company into what it is now. He sold off Rosemont Pharma and pursued gout drug which is a money-losing commercial flop.
Mitch2bdog wrote: "you know jack when it comes to forcasting sales and revenue" Yeah, Woodbarn knows nothing, but he was closer than Zacks analyst. Zacks analyst projected $1 million Soltamox revenue for 2012 and $4 million for 2013 with peak sales of $25 million by 2018. So Soltamox should be doing $1 million a quarter by now according to Zacks analyst.
Wow, Savient Pharma stock now $0.08 down $0.50 after bankruptcy announcement. Savient used to have a market cap of over $500 million with hundreds of million in revenue. That was back when Christopher Clement was CEO, now COO of DARA. Worst move was probably selling off Rosemont Pharma, which was recently sold to Perrigo for over $200 million.
I think most stock is electronically issued and traded now, not printed. Your negative spamming is impressive.
IPCI options are held by employees and executive officers and are issued by the company stock options plan. Hope employees are strong stock holders with long-term view.
HOLYWALLST, IPCI is a pharmaceutical not a biotech. Pharmaceuticals deal with chemicals while biotechs deal with biological stuff. So you are mistaken lumping IPCI with risky development stage biotechs. Lump IPCI with initial commercial stage generic drug companies.
How about getting approval in Canada? IPCI is in Canada. Maybe IPCI could partner with a Canadian company like Apotex or Paladin Labs to get their generic drugs approved in Canada.
So you think you can predict short-term fluctuations of IPCI? Then you will make lots of money trading. Go ahead.
Mitch, what do you think of Soltamox revenue in latest quarter? Did not you say I would get a spanking when September 2013 quarter earnings came out? I think company did not break-down revenue by product in press releases, but Zacks analyst got it out of them. I think he said Soltamox had around $50,000 revenue while Gelclair was $70,000 revenue. So Gelclair outsold Soltamox. Also, Soltamox revenue actually lower than launch quarter. Does not Soltamox have $20-$25 million peak sales project by 2018 by Zacks analyst? Is DARA too embarrassed to reveal the number of prescriptions for Soltamox?
Anyway, maybe company will have better luck with the new three products from Mission Pharmacal. How come the longs on DARA board do not talk about them? Do they even know what they are? I would give the iron supplement the best chance, the other two look like duds to me.